BACKGROUND: Nail changes are a common side effect of taxane chemotherapy, although their correct management is poorly standardized. OBJECTIVE: To evaluate incidence, clinical aspects, and response to treatment of taxane-induced nail side effects in patients treated with taxanes for malignancies. PATIENTS AND METHODS: We performed a retrospective clinical study of 79 patients with taxane-induced nail changes from January 2015 to July 2018. RESULTS: Paclitaxel was the most responsible drug and both hands and feet were often affected (46.8%). Grade 2 nail toxicity was seen in 63.3% of the patients, including painful subungual hematoma, hemorrhagic onycholysis, and paronychia. Grade 3 nail toxicity was seen only in 2.5% of the patients, including hemorrhagic onycholysis and pyogenic granuloma. Removal of the detached nail plate with application of topical antibiotics and steroids induced regression of symptoms within 2 weeks. CONCLUSIONS: Nail toxicity develops mostly at the end of therapy, and total drug dosage is the only known factor that predisposes to these side effects. Trauma possibly plays a role as the most severe signs are located on the great toenails. Although it is impossible to prevent taxane-induced nail side effects, a careful patient monitoring permits to immediately recognize and manage the symptoms in order to induce their remission and improvement of the patient's quality of life.
BACKGROUND: Nail changes are a common side effect of taxane chemotherapy, although their correct management is poorly standardized. OBJECTIVE: To evaluate incidence, clinical aspects, and response to treatment of taxane-induced nail side effects in patients treated with taxanes for malignancies. PATIENTS AND METHODS: We performed a retrospective clinical study of 79 patients with taxane-induced nail changes from January 2015 to July 2018. RESULTS: Paclitaxel was the most responsible drug and both hands and feet were often affected (46.8%). Grade 2 nail toxicity was seen in 63.3% of the patients, including painful subungual hematoma, hemorrhagic onycholysis, and paronychia. Grade 3 nail toxicity was seen only in 2.5% of the patients, including hemorrhagic onycholysis and pyogenic granuloma. Removal of the detached nail plate with application of topical antibiotics and steroids induced regression of symptoms within 2 weeks. CONCLUSIONS: Nail toxicity develops mostly at the end of therapy, and total drug dosage is the only known factor that predisposes to these side effects. Trauma possibly plays a role as the most severe signs are located on the great toenails. Although it is impossible to prevent taxane-induced nail side effects, a careful patient monitoring permits to immediately recognize and manage the symptoms in order to induce their remission and improvement of the patient's quality of life.
Entities:
Keywords:
Breast cancer; Chemotherapy; Hemorrhagic onycholysis; Nail side effects; Taxane
Authors: O Vanhooteghem; B Richert; A Vindevoghel; L Vandenbossche; A Vandeveire; M de la Brassinne Journal: Br J Dermatol Date: 2000-08 Impact factor: 9.302
Authors: Florian Scotté; Eugeniu Banu; Jacques Medioni; Eric Levy; Christelle Ebenezer; Sandrine Marsan; Adela Banu; Jean Marc Tourani; Jean-Marie Andrieu; Stéphane Oudard Journal: Cancer Date: 2008-04-01 Impact factor: 6.860
Authors: Osama Alshari; Abdelwahab Aleshawi; Ahmed H Al Sharie; Ala'a Msameh; Isra Al-Omari; Renad Msameh; Abdallah Almegdadi; Dima Albals Journal: Breast Cancer (Auckl) Date: 2020-06-15